International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

image of commentary-mrowietz
Ulrich Mrowietz, MD
University Medical Center Schleswig-Holstein
Kiel, Germany

PUBLICATION

Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic: Findings from a Global Patient-Reported Cross-Sectional Survey. Cook E, Dand N, Yiu Zenas Zee N, et al. Br J Dermatol. 2022 Feb 1. doi: 10.1111/bjd.21042. Epub ahead of print. PMID: 35104366.

Why this article was chosen

The COVID-19 pandemic has been a significant concern, and vaccination has been crucial worldwide in its combat. The IPC has followed the developments around COVID-19, issued several statements, and provided information through expert videos and commentaries. The IPC has supported collecting real-world data on COVID-19 and psoriasis (PsoProtect and PsoProtectMe registries). Recently Cook et al (Br J Dermatol 2022 (online first)) reported on the interruption of psoriasis care during the COVID-19 pandemic and vaccine hesitancy in patients with psoriasis.

Commentary

Sudden pandemic situations are a significant threat to people with known chronic illnesses representing an additional unexpected burden. Those with limited psycho-social resources and lower resilience are more likely to withdraw from regular care and seek help or information. However, the high proportion of people with psoriasis having interrupted access to care (40.1%), as described in the report by Cook et al, is unexpected. Still, in this report, the data were collected from a multi-national survey (PsoProtectMe) in 89 countries worldwide on 802 patients with psoriasis. In addition, psoriasis patients having interrupted access to care had increased vaccine hesitancy, were more prevalent in non-white ethnic groups, had shorter disease duration, and were less likely to take systemic immunosuppressants.

It is important to note that the disruption of care can be bi-directional. The affected people stopped seeing their treating physicians, but physicians also canceled patients’ appointments. It is worth noting that younger people with psoriasis and more severe disease were more likely to discontinue care, and the rate of vaccine hesitancy was higher in this group. The authors did not speculate about factors driving this coincident finding. This may be due to greater engagement of younger people through social media, in which worries and concerns (e.g., a new type of vaccine, fear of adverse events, etc) are intensively discussed and amplified without direct physician’s input. However, and encouragingly, the rate of vaccine hesitancy, which was 8.3% in the entire patient population, seems low and provides evidence that stakeholders providing care in the different healthcare systems can get through to people with psoriasis.

As reported by Cook et al, these data help identify groups that need correct and unbiased information based on solid and accurate evidence-based medicine.

One thought on “Commentary: Vaccine Hesitancy and Access to Psoriasis Care in the COVID-19 Pandemic

  1. Carl Stewart says:

    An important commentary on vaccine hesitancy and access in the context of psoriasis. Addressing concerns and promoting accessibility is crucial for public health. Thanks for shedding light on this issue.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Categories

Recent Posts

Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

Psoriasis in Older Patients: Key Considerations and Best Practices for Effective Management

Getting to Know IPC’s Board Member Lone Skov: What Inspired Me to Specialize in Psoriasis

Also Read

Oral IL-23 receptor antagonist

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

This commentary provides expert analysis on recent research findings, clinical trial results, and the promising future of therapies for individuals with moderate to severe plaque psoriasis. Uncover the latest advancements in psoriasis treatments, focusing on the significant impact of new biological agents and oral IL-23 receptor antagonists.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.